Introduction
Mental retardation (MR) is a life-long disability with a major impact on the lives of the patients and their families. The prevalence of MR is 2 -3%, and the underlying cause remains unknown in 65 -80% of patients. 1 -3 Diagnosing is a challenge because of the broad spectrum of potentially underlying disorders and the wide range of available tests.
Knowing the cause is necessary for assessing recurrence risk, short-and long-term prognosis and to decide on treatment options. Changes in genetic dosage of one or more genes are common causes of MR. 3 Routine microscopic analysis of chromosomes isolated from peripheral blood lymphocytes has been used successfully to identify such genetic imbalances over the past 50 years. This conventional karyotyping has the advantage of surveying the entire genome for chromosome abnormalities in a single experiment, but it cannot detect imbalances smaller than approximately 5 Mb. Smaller chromosomal aberrations can be identified with fluorescent in situ hybridization (FISH) and multiplex ligation-dependent probe amplification (MLPA) analysis. These techniques are used either to confirm a clinical suspicion by screening for well-known microdeletion syndromes associated with MR or for the analysis of all subtelomeric regions of the genome. The subtelomeric regions are known to be frequently affected in MR. 1 The use of FISH and MLPA analysis is limited because only a few genomic regions can be screened in a single experiment and it can therefore not be applied genome wide.
Patients with unexplained MR with or without multiple congenital abnormalities (MR/MCA), who are referred to genetic laboratories, are initially screened with conventional karyotyping and, if required, with targeted FISH or MLPA analysis. The combined diagnostic yield of these analyses is approximately 5 -10%. 4 Consequently, a clinical diagnosis is lacking in the majority of these patients, which impedes the development of treatment strategies and adequate genetic counseling. Therefore, new highresolution whole-genome technologies facilitating an increased detection rate of subtle chromosome imbalances are needed to improve the diagnosis of MR/MCA patients. Recent developments in array technology allow wholegenome analysis for copy number variants (CNVs) at a resolution 10 -10 000 times higher than that of conventional karyotyping. Comparative genome hybridization (CGH) studies using arrays with large insert clones (usually bacterial artificial clones (BACs)) have shown the potential of array technology to identify diagnostic CNVs in generally 16.7% of the unexplained MR/MCA patients. 4 -11 The pathogenic CNVs detected in CGH studies range in size from 0.25 to 15 Mb. 12 Resolution is limited by the size of the probes and the distance between the clones, that is 100 kb to 1 Mb. Therefore, the ideal technique would identify abnormalities with an even higher resolution. The single-nucleotide polymorphism (SNP) arrays have been widely used for genotyping and can identify submicroscopic CNVs as well as low-level chromosomal mosaicisms and uniparental disomies (UPDs).
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We performed SNP array analysis on DNA from 318 patients with unexplained MR/MCA and an apparently balanced karyotype to search for potentially pathogenic submicroscopic CNVs with two different commercially available SNP array platforms. In this study, we show the importance of implementing the SNP array analysis in a diagnostic setting and advocate a whole-genome copy number screening using an SNP array as a new diagnostic tool for every MR/MCA patient rather than conventional karyotyping.
Materials and methods

Patients
A total of 318 patients referred for MR/MCA were recruited without further selection. Previously performed conventional karyotyping, targeted FISH or molecular tests revealed no etiological diagnosis. Detailed phenotypic information on all patients found to have a pathogenic or potentially pathogenic CNV is provided in Supplementary Table 1 . DNA was extracted from whole blood using a Gentra Puregene DNA Purification Kit (Gentra Systems, Minneapolis, MN, USA), following the manufacturer's instructions. The study was approved by the Leiden University Medical Center Clinical Research Ethics Board, conforming to Dutch law and the World Medical Association Declaration of Helsinki.
SNP arrays
The Affymetrix GeneChip Human Mapping 262K NspI and 238K StyI arrays (Affymetrix, Santa Clara, CA, USA) contain 262 262 and 238 304 25-mer oligonucleotides, respectively, with an average spacing of approximately 12 kb per array. An amount of 250 ng DNA was processed according to the manufacturer's instructions. SNP copy number was assessed using the software program CNAG version 2.0. 16 The Illumina HumanHap300 BeadChip (Illumina Inc., San Diego, CA, USA) contains 317 000 TagSNPs, with an average spacing of approximately 9 kb. The Illumina HumanCNV370 BeadChip (Illumina) contains 317 000 TagSNPs and 52 000 non-polymorphic markers for specifically targetting nearly 14 000 known CNVs. This array has an average spacing of approximately 7.7 kb. A total of 750 ng DNA was processed according to the manufacturer's instructions. SNP copy number (log R ratio) and B-allele frequency were assessed using the software programs BeadStudio version 3.2 (Illumina) and Partek Genomics Suite version 6.3 (Partek Inc., St Louis, MO, USA).
Evaluation of CNVs
Deletions of at least five adjacent SNPs or of a minimum region of 150 kb and duplications of at least seven adjacent SNPs or of a minimum region of 200 kb were analyzed. 17 This approach was adopted to minimize the number of false-positive findings. The detected CNVs were classified into three different groups: I, known pathogenic CNVs (known microdeletion or microduplication syndrome); II, potentially pathogenic CNVs, not described in the Database of Genomic Variants (DGV; The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, Canada, http://projects.tcag.ca/variation/); and III, known polymorphic CNVs described in the DGV or observed in our in-house reference set (60 controls), whereby at least three individuals must be reported with the same rearrangement. All type III CNVs were further excluded from this study.
All type II CNVs were assessed with Ensembl (Wellcome Trust Genome Campus, Hinxton, Cambridge, UK, http:// www.ensembl.org: Ensembl release 52 -December 2008) and DECIPHER (Wellcome Trust Genome Campus, Hinxton, Cambridge, UK) for gene content and similar cases, respectively. All patients with a type II CNV were added to DECIPHER when consent was obtained.
Validation of CNVs
The known and potentially pathogenic CNVs were confirmed with MLPA, FISH or another type of SNP array on a second independent sample. If parents were available, segregation analysis was performed by MLPA, FISH or SNP array.
MLPA experiments were performed as described. 18 At least two synthetic MLPA the probes were designed within the CNV and probes were commercially obtained from Biolegio (Malden, The Netherlands Table 1 shows a summary of all detected CNVs. Six patients showed a CNV that has a clear clinical significance as it overlaps a known microdeletion/duplication syndrome. In eight patients, we detected a CNV that was recently described as a new microdeletion/duplication syndrome. 20 -26 63 Potentially pathogenic CNVs were observed in 52 patients (16.4%). Four patients showed striking regions of loss of heterozygosity (LOH) ( Table 1 and Figure 1 ). Regions of homozygosity, ranging in size from 200 kb to 15 Mb, are common in healthy individuals. 27 Here, four patients showed regions of LOH extending more than 15 Mb. Two patients showed a single segment of LOH (BC227 and BC318) and one patient a single segment, however in mosaic form (BC302), and one patient, two segments (BC308). The parents of the patients were not related. Two patients showed a low-level chromosomal mosaicism. Patient CR355 was a girl diagnosed with microcephaly, ventricular septum defect, diaphragmatic hernia, umbilical hernia and postaxial polydactyly of the left hand (Figure 2g and h). Pregnancy was conceived by in vitro fertilization and the girl was born at a gestational age of 36 5/7 weeks, with a birthweight of 2475 g. Her psychomotor development was delayed and she failed to thrive. She developed severe respiratory insufficiency and died at the age of 7 months. Initial conventional karyotyping of five metaphases did not show rearrangements. SNP array analysis showed a subtle increase in copy number for chromosome 13, suggesting an extra copy of chromosome 13 in 14% of the cells (Figure 2a) . FISH experiments confirmed the presence of trisomy 13 in 18% of cultured lymphocytes (Figure 2c and d) and supplementary karyotyping detected in 7 of the 50 (13%) metaphases an extra chromosome 13. Patient CR377 was a boy referred at the age of 2 years and 9 months because of short stature, speech delay and motor delay ( Figure 2i ). Pregnancy had been uneventful and the boy was born at a gestational age of 40 5/7 weeks after vacuum extraction, with a birthweight of 3610 g. In early childhood, he suffered from recurrent respiratory infections and recurrent otitis media. At referral, his height was 84 cm (À3.4 SD). He had a broad thorax, pectus excavatum, a right-sided simian crease and short second phalanges of both digiti V. On follow-up at the age of 3 years and 7 months, his height was even more compromised (À4.2 SD). At the age of 4 years and 8 months, a marked discrepancy in leg length was noted, the right being shorter. At that time, the skin around both wrists and ankles showed an apparent reticular pattern of hypo-and hyperpigmentation. The body asymmetry combined with an abnormal skin pigmentation pointed in the direction of a mosaic condition. Conventional karyotyping on 31 metaphases had shown one cell with trisomy 14, which, confirming to professional guidelines, was interpreted as an artifact. SNP array results displayed a subtle increase in copy number for chromosome 14, suggesting an extra copy of chromosome 14 in 19% of the cells, and mosaicism was confirmed with FISH experiments on cultured lymphocytes (9%) (Figure 2b ,e and f). UPD of chromosome 14 for the normal cells was excluded (results not shown).
Discussion
In this study, SNP arrays were used to search for pathogenic CNVs in patients with unexplained MR/MCA. The detected CNVs can be divided into the following groups: clearly pathogenic CNVs that overlap known microdeletion/duplication syndromes, CNVs that overlap recently described syndromes, potentially pathogenic CNVs and polymorphic CNVs (Supplementary Table 1 ). In total, we detected known syndromes in six patients, recently described CNVs in eight patients and 63 potentially pathogenic CNVs in 52 patients (in total, 20.7%). The polymorphic CNVs were excluded from further research.
Six CNVs were considered pathogenic as they are associated with well-established microdeletion syndromes. These syndromes were recognized afterwards by a clinical geneticist, which underlines the difficulty of establishing a diagnosis by clinical observation. Eight patients showed CNVs that were recently identified in other studies. For these new syndromes, no obvious phenotype has been established yet, and more patients with the same abnormalities are needed to unravel the associated phenotype. The discovery of these 'known' CNVs highlights the advantage of the whole-genome screening methods to detect a known deletion or duplication syndrome in one single experiment.
Unraveling the clinical relevance for the potentially pathogenic CNVs is a new challenge. Regions containing coding genes can be present in variable copy number without obvious clinical manifestations, which makes it very hard to determine whether a subtle CNV has a clinical significance. Recent papers have already presented flow schemes for the interpretation of these CNVs. 28, 29 In this study, first, all polymorphic CNVs were excluded by comparing against the DGV and our in-house reference set. Second, for all CNVs containing coding genes annotated by Ensembl (release 52, December 2008), the inheritance was determined by checking both parents (if available). For 27 potentially pathogenic CNVs, we could establish that the rearrangement was inherited from one of the unaffected parents. Several studies have shown that some CNVs are indeed polymorphisms contributing to common variations in healthy individuals. 30, 31 A large number of small rearrangements, detected in patients with MR and inherited from phenotypically normal parents, have been reported, whereby it was speculated that some of these imbalances may indeed be benign variations and others are likely to represent susceptibility loci for disease. 32, 33 A particularly intriguing example is the submicroscopic 1q21 deletion, characteristic for thrombocytopenia absent radius syndrome, which is found in all patients with the syndrome, but is inherited from a phenotypically normal parent in a subset of cases. 34 Mechanisms that can explain why some inherited CNVs occasionally result in abnormal development have been postulated. 32, 36 These mechanisms include: a mutation in the same region on the other chromosome; a mutation in one or more unlinked modifying genes; imprinting; mosaicism in one of the parents; or any other unidentified genetic, epigenetic or environmental factor. 21, 32 Furthermore, it is frequently assumed that parents are phenotypically normal, although a closer inspection by a clinical geneticist might reveal subtle anomalies. 32 Twenty-two de novo potentially pathogenic CNVs are detected and are likely to be relevant for the phenotype of the patient. For 14 potentially pathogenic CNVs, the inheritance could not be determined. Interpretation of these CNVs is even more difficult. Attempts should be made to receive DNA from the parents or, alternatively, other relatives. However, for all potentially pathogenic CNVs, phenotypically concordant patients with the same abnormality need to be found to be sure of their pathogenicity. Therefore, databases such as DECIPHER (https://decipher.sanger.ac.uk/) have been created to compile molecular cytogenetic data from clinical studies all over the world to provide the basis for understanding the role of different CNVs in genetic diseases. For the 63 potentially pathogenic CNVs detected in this study, no complete overlapping cases were described in DECIPHER. More array data on MR patients and healthy controls will be needed to determine the clinical relevance of these CNVs.
In 9 of the 26 de novo CNVs (pathogenic and potentially pathogenic), DNA from the parents was tested on SNP array, enabling us to determine the parental origin. Seven CNVs occurred in the paternally derived chromosome. Only two CNVs occurred in maternally derived chromosomes, giving a paternal -maternal ratio of 6:2. Parental origins of microdeletions and duplications have been investigated in several genomic disorders. Deletions in Williams and DiGeorge syndrome were equally of paternal and maternal origin equally. 37 Deletions in neurofibromatosis type 1 and in 1p36 syndrome were predominant on the maternally derived chromosome. 38, 39 By contrast, duplications in Charcot-Marie-Tooth disease type I and deletions in Wolf -Hirschhorn and Cri Du Chat syndromes occur more frequently in the paternally derived chromosome. 40 -42 Much more parent-of-origin data are needed to document the possible existence of regional parental bias. ArrayCGH (aCGH) screenings performed on mentally retarded patients are a powerful tool for the detection of CNVs. 4 -11 These arrays consist of large-insert clones, and the smallest pathogenic CNVs detected are approximately 0.25 Mb. The high-density whole-genome SNP arrays, which were initially developed for genotyping, are now widely used to search for smaller CNVs. 2,13 -15 In approximately 25% of patients with unexplained MR/MCA, CNVs are detected by aCGH and SNP array studies. The array technology is the most effective method resulting in the most clinical diagnoses compared with conventional karyotyping, FISH analysis and mutation screening. Although it was suspected that array analysis would not be able to detect mosaicisms, the aCGH and SNP array techniques actually appear to be more sensitive in detecting low-level mosaicism than conventional karyotyping. 43, 44 If mosaicism is not suspected, the number of cells counted with conventional karyotyping may not be sufficient to detect the aberrant subset of cells, and a single abnormal cell might be interpreted as an artifact of cell culture. 45 Two such cases of low-level mosaicism were reported in this study. Conversely, a disadvantage of using arrays instead of conventional karyotyping is the inability to detect balanced rearrangements. Around 6% of antenatal cases with balanced reciprocal translocations and inversions are associated with abnormal phenotypes. 54 In these cases, the breakpoints of the rearrangement probably disrupt a gene, or small duplications or deletions beyond microscopic resolution are present. The SNP array analysis will (depending on the resolution) detect the small abnormalities, but the disruption of genes will remain unknown. A retrospective Dutch study showed that only approximately 0.78% of potentially pathogenic balanced rearrangements of all referrals will be undetectable by array analysis without conventional karyotyping. 55 The absence of an aberration or the presence of only polymorphic CNVs after SNP array analysis does not exclude a syndrome caused by a mutation at the gene level. Therefore, we emphasize that MR/MCA patients with normal array results should always be referred to a clinical geneticist to exclude such known syndromes. Furthermore, genomic data obtained from the SNP array analysis can be used in future research for association between genetic markers and specific phenotypes to hopefully diagnose even more patients.
In Figure 3 ). We recommend testing every patient first with an SNP array instead of conventional karyotyping. The results will be classified in patients with polymorphic CNVs or no CNV ('normal'), patients with CNVs that overlap known syndromes and patients with potentially pathogenic CNVs. The 'normal' patients could be screened for gene mutation in targeted genes or in the future with whole-genome next-generation highthroughput DNA-sequencing technology. The patients with CNVs overlapping known syndromes are diagnosed and family members could be checked for inheritance and recurrence risk. The inheritance of the potentially pathogenic CNVs should be tested and the patients should be reported in a database such as DECIPHER. The clinical relevance of these CNVs can be determined when the specific CNV is reported in adequate numbers of healthy individuals or phenotypically concordant patients. This new approach will diagnose a larger proportion of CNVs in the first round; however, the interpretation of the CNVs will be the major challenge. Eventually, more families will be informed about the cause of the disease of their family member. This will improve medical care and genetic counseling. Furthermore, as the SNP array approach will make targeted FISH and MLPA analysis redundant, less laboratory tests will be needed, which leads to a substantial reduction of cost.
